The 20 fastest-growing, highest-paying biotechs

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

• We rounded up the 20 fastest growing drugmakers that pay the most;
• The recently approved Alzheimer's treatment could change the way we pay for drugs;
• 5 questions facing GlaxoSmithKline ahead of a big investor meeting.

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...

Here are the 20 fastest growing biotech and pharma companies that pay people the most

• Insider analyzed data from more than 100 drug companies to find which were hiring and paying top wages.
• We found 20 companies that are hiring and typically pay more than $217,000.
• The list includes cancer companies, gene-editing firms, neuroscience startups, and vaccine developers.

Find the full list here>>

Big insurers are considering new ways to pay for Biogen's $56,000-per-year Alzheimer's drug. It could spark changes in how the US and insurers pay for drugs.

• The price tag of new Alzheimer's drug Aduhelm could squeeze Medicare and patients.
• Experts say the cost could prompt Medicare and private insurers to find new ways to pay for drugs.
• Insurers Cigna and Humana are considering contracts to pay for the drug based on how well it works.

Get the full story>>

5 burning questions facing pharma giant GlaxoSmithKline and CEO Emma Walmsley before a crucial investor day

• Leaders of GlaxoSmithKline will present their vision for the pharma giant on Wednesday.
• GSK has faced mounting questions over its vaccine business and cancer-research strategy.

We're watching for five pressing questions that GSK may attempt to answer>>

More stories we're reading:

• The Delta variant might pose the biggest threat yet to vaccinated people (Insider)
• Why an FDA advisory committee member isn't resigning following a controversial Alzheimer's approval (Stat News)
• Supreme Court upholds the Affordable Care Act, ruling that Texas doesn't have standing to challenge Obama's signature healthcare law (Insider)
• Struggling hospitals could be a key part of why a disproportionate number of people who've died from COVID-19 are Black (BuzzFeed News)
• 23andMe just went public. We spoke with its CEO about its road to IPO, and what the future holds for the consumer-genetics industry. (Insider)

- Lydia